What are the NCCN and ESMO recommendation for the evaluation of cell proliferation in the mantle cell lymphoma type of non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


In addition, both the NCCN and ESMO recommend assaying Ki-67 proliferative antigen to evaluate cell proliferation. Low Ki-67 (< 30%) is associated with a more favorable prognosis; however, it is not used to guide treatment decisions. [18, 1]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!